PMID- 37925136
OWN - NLM
STAT- MEDLINE
DCOM- 20231218
LR  - 20240228
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Linking)
VI  - 28
IP  - 12
DP  - 2023 Dec
TI  - Psychedelic renaissance: Revitalized potential therapies for psychiatric 
      disorders.
PG  - 103818
LID - S1359-6446(23)00334-3 [pii]
LID - 10.1016/j.drudis.2023.103818 [doi]
AB  - Psychiatric disorders represent the largest cause of disability worldwide. Global 
      interests in psychedelic substances as potentially therapeutic agents for 
      psychiatric disorders has recently re-emerged. Here, we review progress in the 
      development of psychedelic compounds that have potential therapeutic effects as 
      well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), 
      lysergic acid diethylamide (LSD), and the entactogen 
      3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential 
      interactive effects these compounds can have with psychotherapeutic approaches. 
      We provide a cutting-edge review of active and recently completed clinical trials 
      based on the published literature (from MEDLINE), published abstracts at citable 
      conferences, clinical trials from the US Clinical Trials registry 
      (clinicaltrials.gov) and media press releases.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Rhee, Taeho Greg
AU  - Rhee TG
AD  - Yale Depression Research Program, Department of Psychiatry, Yale School of 
      Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of 
      Connecticut School of Medicine, Farmington, CT, USA.
FAU - Davoudian, Pasha A
AU  - Davoudian PA
AD  - Medical Scientist Training Program, Yale School of Medicine, New Haven, CT, USA; 
      Interdepartmental Neuroscience Program, Yale School of Medicine, New Haven, CT, 
      USA.
FAU - Sanacora, Gerard
AU  - Sanacora G
AD  - Yale Depression Research Program, Department of Psychiatry, Yale School of 
      Medicine, New Haven, CT, USA.
FAU - Wilkinson, Samuel T
AU  - Wilkinson ST
AD  - Yale Depression Research Program, Department of Psychiatry, Yale School of 
      Medicine, New Haven, CT, USA. Electronic address: samuel.wilkinson@yale.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231102
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
RN  - 0 (Hallucinogens)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
RN  - 2RV7212BP0 (Psilocybin)
RN  - WUB601BHAA (N,N-Dimethyltryptamine)
SB  - IM
MH  - Humans
MH  - *Hallucinogens/pharmacology/therapeutic use
MH  - Lysergic Acid Diethylamide/therapeutic use
MH  - *Mental Disorders/drug therapy
MH  - Psilocybin/therapeutic use
MH  - N,N-Dimethyltryptamine/therapeutic use
OTO - NOTNLM
OT  - anxiety
OT  - depression
OT  - posttraumatic stress disorder
OT  - psychedelics
OT  - psychiatric disorders
EDAT- 2023/11/05 00:42
MHDA- 2023/12/18 06:42
CRDT- 2023/11/04 20:19
PHST- 2023/08/08 00:00 [received]
PHST- 2023/10/27 00:00 [revised]
PHST- 2023/10/30 00:00 [accepted]
PHST- 2023/12/18 06:42 [medline]
PHST- 2023/11/05 00:42 [pubmed]
PHST- 2023/11/04 20:19 [entrez]
AID - S1359-6446(23)00334-3 [pii]
AID - 10.1016/j.drudis.2023.103818 [doi]
PST - ppublish
SO  - Drug Discov Today. 2023 Dec;28(12):103818. doi: 10.1016/j.drudis.2023.103818. 
      Epub 2023 Nov 2.